(资料图片)

CFi.CN讯：智飞生物（股票代码：300122）公布2025年年度报告摘要。

2025年末2024年末本年末比上年末增减2023年末调整前调整后调整后调整前调整后总资产31,719,717,303.1349,909,613,835.4051,297,102,050.97-38.16%50,232,190,314.3551,290,197,549.93归属于上市公司股东的净资产15,839,778,818.5330,830,739,408.1030,853,631,670.46-48.66%31,506,080,813.3231,574,956,662.982025年2024年本年比上年增减2023年调整前调整后调整后调整前调整后营业收入8,958,435,384.9626,069,711,361.4426,049,233,909.14-65.61%52,917,767,029.2052,963,916,321.62归属于上市公司股东的净利润-14,723,152,851.992,018,478,513.911,972,494,926.61-846.42%8,069,868,204.158,072,339,433.36归属于上市公司股东的扣除非经常性损益的净利润-14,743,796,350.211,991,386,516.101,962,553,754.41-851.26%7,915,455,262.717,946,410,273.98经营活动产生的现金流量净额5,167,319,683.69-4,413,989,315.20-4,224,116,725.46222.33%8,996,369,981.138,979,380,891.02基本每股收益（元/股）-6.15060.84270.8235-846.89%3.36243.3635稀释每股收益（元/股）-6.15060.84270.8235-846.89%3.36243.3635加权平均净资产收益率-62.67%6.46%6.34%-69.01%29.09%29.21%